Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$159.56 - $209.29 $62.3 Million - $81.7 Million
-390,551 Closed
0 $0
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $45.5 Million - $55.7 Million
-268,031 Reduced 40.7%
390,551 $73.7 Million
Q1 2021

May 17, 2021

BUY
$126.83 - $175.69 $9.7 Million - $13.4 Million
76,497 Added 13.14%
658,582 $93 Million
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $17.4 Million - $20.7 Million
141,109 Added 32.0%
582,085 $75.7 Million
Q3 2020

Nov 16, 2020

SELL
$121.19 - $165.49 $8.06 Million - $11 Million
-66,524 Reduced 13.11%
440,976 $64.2 Million
Q2 2020

Aug 14, 2020

BUY
$104.21 - $156.44 $6.51 Million - $9.78 Million
62,500 Added 14.04%
507,500 $75.2 Million
Q1 2020

May 15, 2020

BUY
$93.12 - $133.99 $1.4 Million - $2.01 Million
15,000 Added 3.49%
445,000 $48.4 Million
Q4 2019

Feb 14, 2020

SELL
$74.51 - $124.23 $22.9 Million - $38.2 Million
-307,500 Reduced 41.69%
430,000 $49.5 Million
Q3 2019

Nov 14, 2019

BUY
$70.9 - $87.82 $13.1 Million - $16.2 Million
185,000 Added 33.48%
737,500 $59.3 Million
Q2 2019

Aug 14, 2019

BUY
$65.86 - $92.79 $9.88 Million - $13.9 Million
150,000 Added 37.27%
552,500 $40.1 Million
Q1 2019

May 15, 2019

BUY
$72.76 - $93.45 $16.9 Million - $21.7 Million
232,500 Added 136.76%
402,500 $37.6 Million
Q4 2018

Feb 14, 2019

BUY
$62.67 - $88.33 $10.4 Million - $14.6 Million
165,460 Added 3644.49%
170,000 $12.4 Million
Q1 2018

May 15, 2018

SELL
$115.92 - $148.54 $53,323 - $68,328
-460 Reduced 9.2%
4,540 $541,000
Q4 2017

Feb 15, 2018

BUY
$114.49 - $139.98 $572,450 - $699,900
5,000
5,000 $635,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $35B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Alkeon Capital Management LLC Portfolio

Follow Alkeon Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alkeon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alkeon Capital Management LLC with notifications on news.